Assembly for injecting a viscous liquid product.

(54) Title: LIQUID AND VISCOSE PRODUCT INJECTION SET.

(54) Title: ASSEMBLY FOR INJECTING A VISCOUS LIQUID PRODUCT.

(57) Summary

The present invention relates to a medical use kit including: - an injection line (1) for the transfer of the product to be injected between a container (3) and the patient, said injection line includes a front tubular part (12) and a rear tubular part (11) and a valve check valve (13) with threshold on the rear tubular part, where said check valve with threshold allows the passage of the liquid product from the container to the patient, - a filling line (2) for the transfer of the product to be injected between a power source (4) and the container by means of the front tubular part, said filling line is adapted to the injection line between the parts tubular front and rear and includes a non-return valve (25) that allows the passage of the liquid product from the power supply to the container, - a coupling interface (26) on the filling line intended to be coupled to a pumping unit (22) that allows the liquid to move between the power supply and the container.

(57) Abstract

The present invention concerns an assembly for medical use comprising: - an injection Une (1) for transferring the product to be injected between a container (3) and the patient, said injection Une comprising an upstream tubular portion (12) and a downstream tubular portion (11) and a check valve (13) with a threshold on the downstream tubular portion, said check valve with a threshold allowing the passage of the fluid product from the container to the patient, - a filling Une (2) for transferring the product to be injected between a supply source (4) and the container via the upstream tubular portion, said filling Une being connected to the injection Une between the upstream and downstream tubular portions and comprising a check valve (25) allowing the passage of the fluid product from the supply source to the container, - a coupling interface (26) on the filling line intend to be coupled to a pumping unit (22) allowing the movement of the liquid between the supply source and the container.

<img file="MX359778B_D0001.tif" />

PATENT TITLE No. 359778

Headlines): MEDEX

Home:

240 Altée Jacques Monod, 69800, filled Park Immeuble M2, Saint-Priest, FRANCE

Name: LIQUID AND VISCOSE PRODUCT INJECTION SET.

Classification:

CIP: CPC:

Inventor (s):

SAMUEL MILCENT

Number:

MX / a / 2014/015303

A61M5 / 148; A61M5 / Q0; A61M5 / 142; A61M39 / 24

A61M5 / 14g3; Αβ1 Í / l5Í0é7; A6W5 / 142; A61M39 / 00; A61M39 / 24

TEKRAS8E; DAMIEN MATRAV; NATHALIE MANEUF; ANNE-MARIE

REQUEST 'j, Pecha' íd $ Pi ^ ú | WÍ | MCiún Internacional:

December 2013

Country:

FR

US

Validity: Twenty years

JUNE PRIORITY Ót. 2012 φ June 2012

<img file="MX359778B_D0002.tif" />

Number:

1255630 61/659,288

Expiration Date: June 13, 2033 /&gt; ',&gt; R%. Ψ and ». '' Ai ,. Λ '^SW

Issue Date: ootybn 9 »2016 _¡ 'i *' t &lt;_{( (}? · · ’ _i

The reference patent is granted based on the RTQp ^ e ^ ad Industrial Law.

In accordance with article 23 of the Law of, the Patent Property, of twenty non-extendable apflS, counted from the date of filing ^ of the application iriJéFR ^ ciortf ^ and will be ^ ^ p ^ go vigerrtbs | üb detechos.

Who subscribes to the present title will found it in the area, the first and sixth fractions III and 7? cough 2 of the Industrial Property Law (Official Gazette of the Federation (&amp; OF,) 06/27/1991, dated February 2, 994, / 10 ^ 9§ &amp; 12/26/1097, 05/17/1999 . 01/26/2004, 06/16/2005, 01/25/2006, 05/06/2009, 01/06/2010, 1OT6 / W0.28 / 06/204 &lt;, ^ 7 / ® / 2012 '() ®) 4 / 2012.01 (θώ ^^ and 13 / 0WW qrtáúlos 1 =&gt;, 3 ° fraction V subsection a), 4 “and 12 ° fractions I and III of the Reglamertto * &lt;N-tastifao MaSiano dí lá.PropteAtd Induefrial (DOF 14 / Í2 / 189S, amended on 07/01/2002, 07/15/2004, 07/28/2004 and 09/07/2007); articles 1, 3, 4 ^^ ftaccté »Mtipciso a), l8íraocWiés I and IWy 3O_of the Organic Statute of the Mexican Institute of Industrial Property (DOF 12/27/1999, Γβί0ΓΠΐ3Λ5 · ^ Ι 78 ​​/ TO26eíWjS4IWX) O46 64 ^ 3Βββ04 ^ | ι4β / Ο ^ Κ&gt; Ο7) ί 4, 3 and 5 “a) of the Agreement that delegates powers to the Deputy Directors General, Óoaí | «l ^» i&gt; | 3 | á68aB ^ ®v ^ Son »teÍ ^ WW» »wlas Regional Offices, Divisional Deputy Directors, Departmental Coordinators and other subordinates of the Mexican Institute ^ M» Property tMestrial. (DOF 12/15/1999, amended on 02/04/2000, 07/29/2004, 08/04/2004 and 09/13/2007). ,

This letter is signed with an advanced electronic signature (FIEL), based on articles 7 SIS 2 of the Industrial Property Law; 3 of its Regulations, and 1 fraction III, 2 fraction V, 26 BIS and 26 TER of the Agreement establishing the guidelines for the use of the Electronic Payment and Services Portal (PASE) of the Mexican Institute of Industrial Property, in the procedures indicated.

THE DIVISIONAL DIRECTOR OF PATENTS

NAHANNY CANAL REYES

<img file="MX359778B_D0003.tif" />

Original string;

NAHANNY MARISOL CANAL REYES | 00001000000403252793 | Administration Service

Tax | 1695 || MX / 201B / 86815 | MX / a / 2014/015303 | PCT patent title | 1223 | GAGV | Page (s) | Fybt6oWbmgw6U9rPAt8iqesOI48 =

Digital stamp:

Uo3DhGXD0vLEshnGum0C72eFbKon3GCRSJvDtCWIgdRNheZKV8Z6ZszLL78NilenVz.JIGgeKvvzwhtO400JJG1 / Htg 3jZ9qvXoZKtYtH80IXp2hmdcndw4khdEuyctTKro + Ta872mwUG7iLyLBw / PTPzgYce7X5GuEwBdyRN2wVTmMVEMw8A 6i8K7QsvDSRkNiNUZ4h314FuvMoLEE02NBOIkoVOC026OEvV5MYIUzN3sr6OnUCkX81o7PZkXPmsLc2OnBuGUIcMMD jWLmCDv8fluzzX9tcJLDANSLsKYTTamPcWYg CSN1hjpSXjo + + + Qik + aq2aK n7axd1zR6u / Og ==

Floor 1 Pueblo Santa Mana Teoepan, Xochimilco, 16020 Ciuuact de México; éb) 5..1340 / 00 www.gob.rnx / nnpi

<img file="MX359778B_D0004.tif" />

MX / 2018/86815

LIQUID AND VISCOSE PRODUCT INJECTION SET

35^8

<img file="MX359778B_D0005.tif" />

MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY

TECHNICAL FIELD

The present invention relates to the general technical field of administering a product, mainly liquid or viscous, to a patient, for example parenterally, optionally from a soft bag.

More precisely, the present invention refers to an assembly for medical use that allows the injection of liquid or viscous product into the human body.

BACKGROUND OF THE INVENTION

Advances in medicine have made it possible to develop various procedures for analyzing and monitoring the condition of patients.

These procedures include tests performed after injecting a contrast product, for example for medical imaging, which also includes X-ray imaging and Magnetic Resonance Imaging (MRI) and nuclear medicine.

In most cases, the contrast product injection operation requires the transfer of the contrast product between a container containing this contrast product and the patient. This transfer is made using a medical kit that includes a

IMPI MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY

<img file="MX359778B_D0006.tif" />

injection line - like a tube connected to the container and to the patient - for the transfer of the contrast product between the container and the patient.

It is often necessary to fill the container with contrast product before transferring it to the patient. In this case, the injection operation comprises:

- a step of filling the container with the contrast product from the power source, and

- a step of transfer of the contrast product between the container and the patient.

For filling the container, for example, a self-contained device is used which enables the container to be filled from a power source.

However, such a solution has the drawback of requiring a significant number of manipulations to:

- the connection / disconnection of the container with the autonomous device, and

- connection / disconnection of the container with the injection line.

These manipulations can reduce the quality of asepsis.

To remedy this drawback, in EP 0 648 513 a medical use set is proposed that includes:

- an injection line for the transfer of the product to be injected between the container and the patient, and

IMPI

MEXICAN INSTITUTE

OF THE PROPERTY

INDUSTRIAL

- a filling line for the transfer of the product to be injected between a power source and the container.

This set has the advantage of limiting the number of connections / disconnections necessary to carry out the container filling step.

Using the medical use kit described in EP 0 648 513, the filling step can be performed according to three different techniques:

i) gravity filling of the power supply:

A drawback of this technique is that the filling time of the container is too long, which prolongs the duration of the injection operation. The two filling techniques described below are intended to reduce the filling duration:

ii) aspiration filling of the product contained in the power supply:

A drawback of this technique is that it can degrade the quality of the contrast product. Indeed, during filling by aspiration mainly through a syringe, a significant depression is created in the filling line and the water that makes up the contrast product can pass into the gas phase. This phenomenon is amplified in the case where the contrast product is heated.

Another drawback of this technique refers to the pressure drops in the filling line. Indeed, since the displacement of the contrast product is induced by the depression created by the syringe, the

IMPI

<img file="MX359778B_D0007.tif" />

The speed of movement of the contrast product is limited by the pressure difference generated between atmospheric pressure and the pressure in the syringe, be it a physical limit of one bar;

iii) filling by pressurization of the power supply:

A drawback to this technique is that it can only be done with a rigid power supply. Also, this technique can only be performed at a very low pressure (less than a bar) to limit the risks of leakage. Finally, this technique does not allow determining the amount of product transferred between the primary source and the container.

An objective of the present invention lies in proposing a medical use kit that allows alleviating at least one of the aforementioned drawbacks.

BRIEF DESCRIPTION OF THE INVENTION

To this end, the invention proposes a set for medical use for the injection of a liquid or viscous product to a patient, as a contrast product, characterized in that the set comprises:

- an injection line for the transfer of the product to be injected between a container and the patient, where said injection line includes a front tubular part, a rear tubular part and a non-return valve with a threshold on the rear tubular part, where said check valve with threshold allows the passage of the liquid product from the

IMPI

MEXICAN INSTITUTE OF ^fwopSPAJi INDUSTRIAL

<img file="MX359778B_D0008.tif" />

container towards the patient,

- a filling line for the transfer of the product to be injected between a power source and the container by means of the front tubular part, where said filling line is adapted to the injection line between the front and rear tubular parts and they comprise a non-return valve that allows the passage of the liquid product from the power supply to the container,

- a coupling interface on the filling line intended to be coupled to a pumping unit that allows the liquid to move between the power supply and the container.

The following are some preferred and non-limiting aspects of the medical use kit according to the invention:

- the filling line comprises a pipe in front of the coupling interface and a pipe after the coupling interface, where the hardness of the pipe in front of the coupling interface is greater than the hardness of the pipe after the coupling interface;

- the hardness of the pipe in front of the coupling interface is equal to or greater than 70 ShA (the Shore hardness, expressed in Shore A or ShA, corresponds to a unit of measurement of the hardness of elastomers or of certain plastic materials widely known by the specialist in the field and recognized by international standards ISO 868 and 7619, ASTM D 2240 and DIN 53505);

- the filling line includes a pipe in front of the interface

IMPI

<img file="MX359778B_D0009.tif" />

coupling and a pipe behind the coupling interface, where the internal diameter of the pipe in front of the coupling interface is greater than the internal diameter of the rear tubular part of the injection line;

- the internal diameter of the pipe in front of the coupling interface is between 3 and 6 millimeters;

- the filling line comprises a pipeline in front of the coupling interface and a pipeline after the coupling interface, where the hardness of the pipeline after the pumping unit is less than the hardness of the rear tubular part of the injection line;

- the shore hardness of the pipe after the pumping unit is between 60 and 80 ShA;

- the filling line comprises a pipe in front of the coupling interface and a pipe after the coupling interface, where the diameter of the pipe after the coupling interface is greater than the diameter of the rear tubular part of the injection line;

- the medical use set further comprises the container, where said container is connected to the injection line before use;

- the container is a bag composed of two overlapping sheets of material and welded to its periphery to define a space intended to contain the liquid or viscous product;

- the medical use set also includes an immovable connection between the container and the injection line.

IMPI

MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY

The reader will appreciate that the medical use kit can be used in an injector of the type described in French patent application no. FR 1255530 filed in the name of the MEDEX company. In this case, the container of the medical use set is a bag that includes sheets 5 superimposed and welded to its periphery and a conduit for the passage of the liquid or viscous product. This bag is intended to be located in the injector so that the bag duct constitutes the element of the bag furthest from the ground, so that an eventual volume of air contained in the bag is in contact with the duct when the bag is full of liquid or viscous product 10.

<img file="MX359778B_D0010.tif" />

BRIEF DESCRIPTION OF THE FIGURES

Other characteristics and advantages of the invention will result from the following description, which is merely illustrative and not restrictive, and should be read with respect to Figure 1 which illustrates an embodiment of a kit for medical use for the injection of a liquid product or slimy to a patient.

IMPI

<img file="MX359778B_D0011.tif" />

DETAILED DESCRIPTION OF THE INVENTION

As indicated above, an injection operation generally comprises two phases:

- a phase of filling a container with a product to be injected, and

- a phase of administration of the product to the patient from the container.

Indeed, the container used at the time of an injection operation is generally empty to allow the user to use it with different types and / or concentrations of products to be injected.

The medical use injection set described below allows these two phases (i.e., filling / administration) to be performed at the time of an injection operation.

General features

Referring to Figure 1, an embodiment of the medical use kit for injecting a patient with a liquid or viscous product, such as a contrast product, is illustrated.

The medical use set comprises an injection line 1 and a filling line 2. The injection line 1 allows the transfer of the product to be injected between a container 3 and the patient. The line of

IMPI

<img file="MX359778B_D0012.tif" />

Fill 2 allows the transfer of the product to be injected between a primary power source 4 and container 3.

The presence of a filling line 2 makes it possible to improve the asepsis of the injection operation and the number of connections / disconnections necessary to allow filling of container 3 is limited.

The medical use set also comprises a coupling interface 26 on the filling line 2. This coupling interface 26 allows a pumping unit 22 to be coupled to the filling line of the medical use set.

The presence of a coupling interface 26 when associated with a pumping unit 22 allows to accelerate the filling speed while limiting the risks of degradation of the quality of the liquid product displaced between the primary power source 4 and the container 3.

The pumping unit 22 may be a peristaltic pump consisting of rollers and a motor - and the coupling interface 26 may be a soft tube intended to contact the rollers of the peristaltic pump. The diameter, the thickness and the elasticity of the soft tube are adapted to allow improving the coupling of the filling line 2 with the pumping unit 22. In particular, the pumping interface can be a tube:

- internal diameter between 2 and 8 millimeters, preferably between 3 and 6 millimeters and more preferably

IMPI

<img file="MX359778B_D0013.tif" />

equal to 4.8 millimeters,

- thickness between 1 and 3 millimeters, preferably between 1 and 2 millimeters and more preferably equal to 1.6 millimeters, and

- Shore A hardness between 55 and 75 ShA, preferably between 55 and 65 ShA and more preferably equal to 60 ShA.

The presence of a coupling interface 26 integrated into the filling line 2 makes it possible to avoid direct contact of the pumping unit 22 with the injectable solution.

In this way, it is no longer necessary to clean the pump unit every time the power supply is replaced, and especially when the power supplies used successively contain products of different natures.

The asepsis of the filling operation is also improved, since the pumping unit 22 is not directly connected to the medical use set, but is coupled to it by means of the coupling interface 26.

Injection line

Injection line 1 includes a front tubular part 12, a rear tubular part 11 and a three-input connector 14 - mainly of the Y or T connector type - between the front and rear tubular parts 11, 12. The

IMPI MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY

<img file="MX359778B_D0014.tif" />

Three-input connector 14 allows filling line 2 to be connected to injection line 1.

One of the ends of the injection line 1 comprises an adaptation element - such as a luer lock - intended to be connected to an injection line 15. This injection line 15 is, for example, a catheter, a hypodermic or intravenous needle or any other type of injection line known to the person skilled in the art.

The other end of the injection line 1 is connected to the container 3 intended to contain the product to be injected into the patient.

Advantageously, the container 3 can be integrated into the medical use set. In other words, the medical use set comprises container 3. In this case, container 3 is previously connected to injection line 1 at the time of manufacturing the medical use set.

In this way, the user has no need to connect the container 3 to the injection line 1 at the time of using the medical kit.

This allows limiting the number of manipulations necessary to install the medical use set. This also allows to increase the asepsis of the group for medical use. Finally, this allows the risks of error to be limited - for example, linked to the connection of a container not adapted to the medical use set - when installing the medical use set.

IMPI

MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY

Preferably, the medical use kit c.nmprpndA arifimás. an immovable connection 31 between container 3 and injection line 1. This limits the risk of disconnection between container 3 and injection line 1.

In the context of the present invention, an immovable connection is understood to be an element (for example a solder, a collage or any other element known to the person skilled in the art) that allows a permanent assembly of two parts so that these two parts they cannot be reciprocally separated, where the assembly of the two parts by this element is carried out before the use of the assembly, mainly at the time of manufacturing the assembly.

In all cases, the container 3 intended to contain the product to be injected can be:

- a syringe composed of a cylindrical body in which a piston covered with an elastomeric gasket is located on its front face, where said piston is able to move in motion between a retracted position (in which the syringe is empty) and a position unfolded (in which the syringe is full of the product to be injected),

- a soft bag composed of, for example, two superimposed sheets and welded to its periphery to define a space intended to contain the liquid or viscous product,

- or any other type of container known to the specialist

<img file="MX359778B_D0015.tif" />

in the matter.

<img file="MX359778B_D0016.tif" />

MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY

<img file="MX359778B_D0017.tif" />

However, in some embodiments, a bag-like container 3 will be privileged, mainly to improve the asepsis of the medical use set. Indeed, in the case of a syringe-like container 3, the internal portion of the cylindrical body located behind the elastomeric gasket is in contact with the ambient air, which, when the piston moves between the deployed and retracted positions, can decrease asepsis.

Injection line 1 can also comprise a non-return valve 13 on the rear tubular part 11. This non-return valve 13 allows the passage of liquid in a single direction, namely from container 3 to the patient.

Advantageously, the non-return valve 13 can have a high opening threshold (that is, greater than 500 mbar). This makes it possible to avoid the risks of transferring the liquid product directly to the patient (without going through the container) at the time of the filling phase.

The non-return valve 13 can also have a higher opening threshold, mainly greater than 1.5 bar (ideally greater than or equal to 2 bar) to allow the use of the medical use kit in an injector of the type described in the French patent application n ° FR 1255530 in the name of the MEDEX company.

Such an injector comprises a box consisting of two hinged half shells to allow the relative displacement of the half shells respectively between:

an open position for the location of container 3 of the

IMPI

MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY

<img file="MX359778B_D0018.tif" />

medical use set, and

- a closed position for carrying out the filling and administration phases.

One of the half shells comprises a bladder called an active-deformable bladder with variable volume under the action of a hydraulic power source that supplies said bladder with hydraulic fluid. The other half shell comprises a deformable pad with constant volume - called a passive pad.

The fact that the threshold opening of the valve with threshold is greater than 1.5 bar (and preferably greater than or equal to 2 bar) ensures that the container is positioned well against the bladder and the pad. This location is necessary to allow the injector to control:

- the amount of contrast product injected into the patient at the time of an administration phase,

- the quantity of contrast product introduced into the container at the time of a filling phase.

Indeed, at the time of an administration phase, the operating principle of this injector is as follows: the bladder is filled with hydraulic fluid so that the walls of the container are located against the walls of the pad and the bladder. When the bladder and pad walls are placed against the container, the introduction of a certain amount of hydraulic fluid into the interior of the bladder induces

<img file="MX359778B_D0019.tif" />

MEXICAN INSTITUTE

OF INDUSTRIAL PROPERTY

<img file="MX359778B_D0020.tif" />

expulsion of the same quantity of contrast product out of the container.

For example, a millimeter of incompressible fluid introduced into the bladder mechanically pushes a millimeter of contrast product out of container 3. In this way, when the walls of the container are located against the bladder and the pad, it is possible to precisely control the amount of product injected into the patient by measuring the amount of hydraulic fluid introduced into the bladder.

At the time of a filling phase, the operating principle of this injector is as follows: the bladder is filled with hydraulic fluid so that the walls of the container are located against the pad and the bladder. The introduction of contrast product into the container induces an increase in its volume that tends to apply a pushing force on the pad and the bladder. This force induces the expulsion of hydraulic fluid out of the bladder. More precisely, when the walls of the container are located against the bladder and the pad, the introduction of a certain amount of contrast product inside the container induces the expulsion of the same amount of hydraulic fluid outside the bladder. In this way, when the walls of the container are located against the bladder and the pad, it is possible to precisely control the amount of contrast product introduced into the container by measuring the amount of hydraulic fluid expelled from the bladder.

The fact that the threshold valve opening threshold is greater than 1.5 bar (and preferably greater than or equal to 2 bar) allows

IMPI

<img file="MX359778B_D0021.tif" />

ensure a good location of container 3 on the vej¡¡ before the slightest displacement of contrast product outside the container is carried out, where the displacement of contrast product outside the container requires a minimum pressure of 1.5 bar in the container .

Filling line

The filling line 2 comprises a pipe 21 in front of the coupling interface 26 and a pipe 23 after the coupling interface 26.

In a variant embodiment, the length of the pipe 21 in front of the coupling interface 26 is between 400 and 800 millimeters in order to limit the pressure drops between the coupling interface 26 and the power supply 4 at the time of suction of the fluid for filling the container 3.

Also, the internal diameter of the pipe 21 in front of the coupling interface 26 may be greater than the internal diameter of the rear tubular part 11 of the injection line 1. In particular, the internal diameter of the pipe 21 in front of the drive unit pumping 22 can be between 3 and 6 millimeters.

Maximizing the internal diameter of the pipe 21 against the coupling interface 26 allows to limit the pressure drops between the primary power supply 4 and the coupling interface 26 at the moment

IMPI

<img file="MX359778B_D0022.tif" />

sucking fluid to fill container 3.

Furthermore, the hardness of the pipeline 21 against the coupling interface 26 may be greater than the hardness of the pipeline 23 after the coupling interface 26. In particular, the hardness of the pipeline 21 against the coupling interface 26 may be equal to or greater than 70 ShA. The fact of having a pipe 21 with a hardness equal to or greater than 70 ShA makes it possible to avoid adhering when aspirating the fluid for filling the container 3. Preferably, the hardness of the pipe is selected to less than 90 ShA to facilitate winding at the time of packaging and facilitate its handling by the operator at the time of installation on the injector.

Advantageously, the hardness of the pipe 23 after the coupling interface 26 can be selected to be less than the hardness of the rear tubular part 11 of the injection line 1. Mainly, the shore A hardness of the pipe 23 after the interface coupling 26 can be between 60 and 80 ShA.

The fact that the hardness of the pipe 23 is less than or equal to 80 ShA allows the filling line 2 to absorb the pulsations eventually generated by the pumping unit 22 to limit the risks of excessive pressure in the medical use set, excessive pressure which could induce a leak of product towards the patient through the check valve 13 with high threshold of the injection line 1. The fact that the hardness of the pipe 23 is greater than or equal to 60 ShA allows limiting the risk of rupture of this pipe 23 under the effect of pressure.

i® IMPI

MEXICAN INSTITUTE Dt LA »K&gt; Hí DAD INDUJTUAL

In a variant, the diameter of the pipe 23 after the coupling interface 26 can be selected to be greater than the diameter of the rear tubular part 11 of the injection line 1. Mainly, the diameter of the pipe 23 after the coupling interface 26 It can be between and 6 millimeters. Even in this case, this makes it possible to absorb the pulsations generated by the pumping unit 22.

The filling line 2 can also comprise a non-return valve 25 that allows the passage of liquid in a single direction, namely, from the primary power supply 4 to the container 3. The presence of a non-return valve 25 allows the line of isolation to be isolated. filling 2 once the filling phase is completed, and this without requiring manipulation by the user before carrying out the phase of administration of the product to the patient.

The filling line 2 can comprise a bubble collector 24 - like a dropper chamber - between the primary power source and container 3. This bubble collector 24 allows air to be removed between the primary power source 4 and container 3.

Set working principle

The principle of operation of the medical use set described above is as follows: at the time of performing a product injection operation on a patient, the user removes the medical use set from the packaging. Connect:

- the free end of fill line 2 to the source of

<img file="MX359778B_D0023.tif" />

IMPI

INSTITUTO MEX1CA NO DE LA PROFIEDAO INDUSTRIAL

<img file="MX359778B_D0024.tif" />

primary feed 4, and

- the free end of injection line 1 to the patient, after having purged it.

When the container 3 is integrated into the assembly, no connection stage is necessary, which limits the risks of contamination of the assembly at the time of its installation.

The user then activates the filling phase. The pumping unit 22 is actuated to fill the container 3 with the product to be injected. The product to be injected is moved between the primary power source 4 and the container 3. The non-return valve 13 with high activation threshold prevents the passage of the product in the rear tubular part 11 of the injection line 1 to avoid any risk of untimely exit of the product to be injected towards the free end of the injection line 1 in the time of the filling phase.

Container 3 is filled with the product to be injected. When the quantity of product contained in container 3 is sufficient, the user interrupts the filling phase to start the phase of administration of the product to the patient after purging the air initially contained in filling lines 2 and injection lines 1.

Container 3 is placed under pressure - for example using a pouch injector or syringe pump device - to induce product displacement between container 3 and the patient.

Non-return valve 25 in filling line 2 prevents passage

IMPI

MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY of the product between container 3 and primary feeding source 4. The product passes through the injection line 15 and enters the patient.

When a sufficient quantity of product has been administered to the patient, the administration phase is interrupted, either automatically or by the user.

In this way, the set described above allows rapid transfers of liquid or viscous product between:

- a primary power source 4 and a container 3, and

- container 3 and a patient, at the same time limiting the 10 risks of contamination by the user.

The reader will understand that numerous modifications can be made to the medical use kit without substantially abandoning the novelty elements and advantages described herein.

Accordingly, all such modifications are incorporated within the scope of the appended claims.

IMPI

<img file="MX359778B_D0025.tif" />